Skip to main content
letter
. 2015 Jun;100(6):e223–e225. doi: 10.3324/haematol.2014.118034

Figure 2.

Figure 2.

Proportion of patients with a certain gene mutation that did or did not progress from myelodysplastic syndromes to acute myeloid leukemia. Blue bars consist of MDS with subsequent progression to AML and AML with an identified preceding diagnosis of MDS (n=39). Red bars consist of all cases from the myelodysplastic syndromes cohort without a known progression to acute myeloid leukemia (n=89). Median follow up was 57.3 months (9.7–113, SD±27.0) for MDS and 88.5 months (27.6–190, SD ±40.5) for acute myeloid leukemia patients.